Cardio-kidney-metabolic protective effects of semaglutide across the spectrum of chronic kidney disease

Figure 1 The effects of semaglutide on the primary Kidney Outcome end-point in recent major clinical trials. FLOW: Evaluate Renal Function with Semaglutide Once Weekly. Primary kidney Outcome- New or worsening nephropathy: Macroalbuminuria, doubling of serum creatinine with estimated glomerular filtration rate (eGFR) ≤ 45, initiation of renal replacement, or renal death. SELECT: Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity. Primary Kidney Outcome- Composite: ≥ 50% decline in eGFR, kidney failure, or kidney-related death. SUSTAIN-6: Semaglutide Use to Stabilize and Improve Glycemic Control in Individuals with Type 2 Diabetes. Primary Kidney Outcome- New or worsening nephropathy: Macroalbuminuria, doubling of serum creatinine with eGFR ≤ 45, initiation of renal replacement, or renal death. SOUL: Semaglutide Cardiovascular Outcomes Trial. Primary Kidney Outcome- Includes: Cardiovascular death, kidney death, ≥ 50% eGFR decline, sustained eGFR < 15, or initiation of dialysis/transplant. eGFR: Estimated glomerular filtration rate; ACR: Albumin to creatine ratio.